Atlas Trials

Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Clinical trial NCT05575973 · UNKNOWN

Trial details

NCT number
NCT05575973
Sponsor
Jianfeng Zhou
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Diffuse Large B-cell Lymphoma
Start date
2022-10-10
Primary completion
2025-07-01
Enrollment
55

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.